<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31936">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02111018</url>
  </required_header>
  <id_info>
    <org_study_id>CytoSorb 2013-001</org_study_id>
    <nct_id>NCT02111018</nct_id>
  </id_info>
  <brief_title>Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Antonio Military Medical Center (SAMMC), US Army Institute of Surgical Research-Burn Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized non-blinded, controlled study to assess the feasibility of the
      CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring
      renal replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of device as measured by change in myoglobin</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of serious device or procedure-related adverse events</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rhabdomyolysis</condition>
  <arm_group>
    <arm_group_label>CVVH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CytoSorb Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb Device</intervention_name>
    <arm_group_label>CytoSorb Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CVVH</intervention_name>
    <arm_group_label>CVVH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is age 18-80

          -  Subjects present with rhabdomyolysis

          -  Subject requires renal replacement therapy and has undergone adequate volume
             resuscitation

          -  Subject is willing to comply with specified follow up requirements

        Exclusion Criteria:

          -  Subject or their legal guardian either declines or cannot give informed consent

          -  Subject is pregnant

          -  Subject has been previously enrolled in this clinical study

          -  Comorbid condition that may limit survival to â‰¤14 days

          -  Comorbid condition that could confound study results

          -  Subjects who are receiving immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>LTC Kevin Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Antonio Military Medical Center-US Army Institute of Surgical Research-Burn Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MAJ Ian Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Antonio Military Medical Center-US Army Institute of Surgical Research- Burn Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Antonio Military Medical Center- US Army Institute of Surgical Research- Burn Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Stewart, MD</last_name>
      <phone>210-916-6152</phone>
      <email>ian.j.stewart6.mil@mail.mil</email>
    </contact>
    <investigator>
      <last_name>MAJ Ian Stewart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LTC Kevin Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhabdomyolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
